

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/665,844	09/19/2003	Kevin R. Stone	082066-0111	6044
48329 7590 10/09/2007 FOLEY & LARDNER LLP 111 HUNTINGTON AVENUE 26TH FLOOR BOSTON, MA 02199-7610			EXAMINER	
			SAUCIER, SANDRA E	
			ART UNIT	PAPER NUMBER
2001011, 1111 02133 7010			1651	•
			MAIL DATE	DELIVERY MODE
•			10/09/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

- <del>-</del> -					
	Application No.	Applicant(s)			
· ,	10/665,844	STONE ET AL.			
Office Action Summary	Examiner	Art Unit			
	Sandra Saucier	1651 ·			
The MAILING DATE of this communication ap Period for Reply	pears on the cover sheet with the	correspondence address			
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D.  - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period.  - Failure to reply within the set or extended period for reply will, by statut Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	OATE OF THIS COMMUNICATION  136(a). In no event, however, may a reply be will apply and will expire SIX (6) MONTHS from the course the application to become ABANDON	ON. timely filed om the mailing date of this communication. NED (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on 17 J	<u>luly 2006</u> .				
2a)⊠ This action is <b>FINAL</b> . 2b)☐ Thi	This action is <b>FINAL</b> . 2b) This action is non-final.				
	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is				
closed in accordance with the practice under	Ex parte Quayle, 1935 C.D. 11,	453 O.G. 213.			
Disposition of Claims					
4)⊠ Claim(s) 1 is/are pending in the application.					
4a) Of the above claim(s) is/are withdra	wn from consideration.				
5) Claim(s) is/are allowed.					
6)⊠ Claim(s) <u>1</u> is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/o	or election requirement.				
Application Papers					
9) The specification is objected to by the Examine	er.				
10) The drawing(s) filed on is/are: a) acc	cepted or b) objected to by the	e Examiner.			
Applicant may not request that any objection to the	drawing(s) be held in abeyance. S	ee 37 CFR 1.85(a).			
Replacement drawing sheet(s) including the correct	ction is required if the drawing(s) is o	bjected to. See 37 CFR 1.121(d).			
11)☐ The oath or declaration is objected to by the E	xaminer. Note the attached Office	e Action or form PTO-152.			
Priority under 35 U.S.C. § 119					
12) ☐ Acknowledgment is made of a claim for foreign a) ☐ All b) ☐ Some * c) ☐ None of:	n priority under 35 U.S.C. § 119(	a)-(d) or (f).			
1. Certified copies of the priority documen					
2. Certified copies of the priority documen	• •				
3. Copies of the certified copies of the price	· ·	ved in this National Stage			
application from the International Burea  * See the attached detailed Office action for a list	, , , , , , , , , , , , , , , , , , , ,	ved.			
dee the attached detailed Office deticit for a list	of the defined deplet not recent	vou.			
Attachment(s)					
Notice of References Cited (PTO-892)     Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summa Paper No(s)/Mail I				
3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 7/17/06.	5) Notice of Informal 6) Other:				

Art Unit: 1651

## **DETAILED ACTION**

Claim 1 is pending and is considered on the merits.

## Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claim 1 remains rejected on the ground of nonstatutory obviousnesstype double patenting as being unpatentable over claims 2 and 7 of U.S. Patent No. 5,902,338 [A]. Although the conflicting claims are not identical, they are

Art Unit: 1651

not patentably distinct from each other because the claims of US 5,902,338 have a non-limiting range of glycosidase which encompasses the instant range of about 1 mU/ml to about 1000U/ml.

Claim 1 remains rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-8 of U.S. Patent No. 6,110,206 [B].

Although the conflicting claims are not identical, they are not patentably distinct from each other because the claims of US 6,110,206 have a non-limiting range of glycosidase which encompasses about 1mU/ml to about 1000U/ml as instantly recited.

Claim 1 remains rejected on the ground of nonstatutory obviousness—type double patenting as being unpatentable over claims 1–17 of U.S. Patent No. 6,210,440 [C]. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claim is open to further steps of which treatment with sialic acid is one of the optional treatments described in the instant specification. Thus, the instant claim is broader and encompasses the claims of US 6,210,440.

Claim 1 remains rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over at least claims 1-5 of U.S. Patent No. 6,231,608 [D]. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claims are open to further treatment with an aldehyde as described in paragraph 39 of the instant specification. Thus, the instant claims are co-extensive to the claimed method of US 6,231,608.

Claim 1 remains rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-11 of U.S. Patent No. 6,402,783 [E]. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claim is open to

Art Unit: 1651

further steps such as a capping step which is described in the instant specification. Thus, the instant claim is broader and encompasses the claims of US 6,402,783.

Claim 1 remains rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over at least claims 1, 2, 4, 5, 7-10 of U.S. Patent No. 6,758,865 [F]. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claim is open to further steps such as capping with fucosyl, sialyl and other molecules (paragraph 0046).

## Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Applicant should specifically point out the support for any amendments made to the disclosure, including the claims (MPEP 714.02 and 2163.06). Due to the procedure outlined in MPEP 2163.06 for interpreting claims, it is noted that other art may be applicable under 35 USC 102 or 35 USC 103(a) once the aforementioned issue(s) is/are addressed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sandra Saucier whose telephone number is (571) 272-0922. The examiner can normally be reached on Monday

Art Unit: 1651

through Friday, if attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, M. Wityshyn can be reached on (571) 272-0926. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Sandra Saucier Primary Examiner Art Unit 1651